Emerald Kalama to Acquire Innospec Widnes

US-based Emerald Kalama Chemical has agreed to acquire Innospec Widnes, based at Widnes, UK, for an undisclosed sum.
Currently a subsidiary of Innospec Inc., the British company is a leading manufacturer of high-purity aroma chemicals used to add fragrance to perfumes and household products.
The acquired business will be incorporated into the Emerald Kalama Chemical flavor and fragrance business, based in the US state of Ohio.
Calling it a “great fit,” Peter M. Fielder, vice president of the business line, said the acquisition of Innospec Widnes will accomplish several key strategic goals. It will be “a significant step” toward expanding the US company’s footprint, global reach and service to customers in the flavor and fragrance industry. At the same time, it will increase its manufacturing capabilities and provide a base from which to serve customers in Europe and the rest of the world.
Addition of the Innospec Widnes products will roughly double Emerland’s range of aroma chemicals, Fielder added.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.